## IHS Diabetes Care and Outcomes Audit, 2022

**NOTE**: It is highly recommended that you review the <u>Audit 2022 Instructions</u> prior to conducting an Audit.

Audit Period Ending Date: 12 / 31 / 2021	Examinations (during Audit period)
Facility Name:	Foot (comprehensive or "complete", including evaluation of
Reviewer initials:	sensation and vascular status): □1 Yes
State of residence:	□2 No
<del></del>	Eye (dilated exam or retinal imaging):
Month/Year of Birth:/	□1 Yes
Sex: ☐1 Male	□2 No
☐2 Female	Dental:
☐3 Unknown	□1 Yes
Date of Diabetes Diagnosis:/	□2 No
DM Type:   Type 1	Mental Health
□2 Type 2	Depression an active problem/diagnosis:
Tobacco/Nicotine Use	□1 Yes
Screened for tobacco use (during Audit period):	□ □2 No
□1 Yes	Screened for depression (during Audit period):
□2 No	□1 Yes
Tobacco use status (most recent):	□2 No
□ 1 Current user	Education (during Audit period)
□2 Not a current user	Nutrition:
☐3 Not documented	□1 RD □3 Both RD and Other □2 Other
Tobacco cessation counseling/education received (during	□4 None
Audit period):	Physical activity:
☐1 Yes	□1 Yes
□2 No	□2 No
Electronic Nicotine Delivery Systems (ENDS)*	Other diabetes:
Screened for ENDS use (during Audit period):	□1 Yes
□1 Yes	□2 No
□2 No	Diabetes Therapy
ENDS use status (most recent):	Select all prescribed (as of the end of the Audit period):
□1 Current user	☐1 None of the following
2 Not a current user	_
☐3 Not documented	□2 Insulin
*ENDS include: vapes, vaporizers, vape pens, hookah pens, electronic	☐3 Metformin [Glucophage, others]
cigarettes (e-cigarettes or e-cigs), and e-pipes.	☐4 Sulfonylurea [glipizide, glyburide, glimepiride]
Vital Statistics	☐5 DPP-4 inhibitor [alogliptin (Nesina), linagliptin (Tradjenta), saxagliptin (Onglyza), sitagliptin (Januvia)]
Height (last ever): ft in	GLP-1 receptor agonist [dulaglutide (Trulicity), exenatide (Byetta Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin),
Weight (last in Audit period): lbs	semaglutide (Ozempic, Rybelsus, Wegovy)]
Hypertension (documented diagnosis ever):  □1 Yes	□7 SGLT-2 inhibitor [canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro)] □8 Pioglitazone [Actos] or rosiglitazone [Avandia]
□2 No	☐9 Acarbose [Precose] or miglitol [Glyset]
Blood pressure (last 3 during Audit period):	
/mmHg	10 Repaglinide [Prandin] or nateglinide [Starlix]
<del></del>	☐11 Pramlintide [Symlin]
/mmHg	☐12 Bromocriptine [Cycloset]
/mmHg	☐13 Colesevelam [Welchol]

Version: 7/9/2021 Page **1** of **2** 

**CONTINUED ON PAGE 2.** Be sure to complete both pages for

all Audited patients.

## PAGE 2

ACE Inhibitor or ARB	
Prescribed (as of the end of the Audit period):	
□1 Yes □2 No	
Commonly prescribed medications include: <u>ACE Inhibitors:</u> benazepril, captopril, enalapril, fosinopril, lisinopril, ramipril <u>ARBs:</u> candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan	
Aspirin or Other Antiplatelet/Anticoagulant Therapy	
Prescribed (as of the end of the Audit period):	
□1 Yes	
□2 No	
Commonly prescribed medications include: <u>Anticoagulants:</u> apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), enoxaparin (Lovenox), rivaroxaban (Xarelto), warfarin (Coumadin) <u>Antiplatelets:</u> aspirin, aspirin/dipyridamole (Aggrenox), cilostazol (Pletal), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta)	
Statin Therapy	
Prescribed (as of the end of the Audit period): ☐1 Yes ☐2 No ☐3 Allergy/intolerance/contraindication	
Commonly prescribed medications include: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin	
Cardiovascular Disease (CVD)	
Diagnosed (ever): ☐1 Yes ☐2 No	
Tuberculosis (TB)	
TB diagnosis (latent or active) documented (ever):  — □1 Yes — □2 No	
TB test done (most recent):  ☐ □1 Skin test (PPD) ☐ □2 Blood test (QFT-GIT, T-SPOT) ☐ 3 No test documented	
TB test result: ☐ 1 Positive ☐ 2 Negative	
☐3 No result documented	
If TB diagnosed and/or test result positive, treatment initiated (e.g., isoniazid, rifampin, rifapentine, others):  1 Yes 2 No 3 Unknown	
If TB result negative, test date:	
Date:/	

Hepatitis C (HCV)	
HCV diagnosed (ever):  □1 Yes	
□ □2 No	
□1 Yes	/, screened at least once (ever):
□2 No	
Retinopathy	
Diagnosed (ever):	
∐1 Yes □2 No	
Amputation	
	type (e.g., toe, partial foot, above
or below knee):	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
□1 Yes	
□2 No	
Immunizations	
Influenza vaccine (during Aud  ☐1 Yes	dit period):
□2 No	
Pneumovax/PPSV23 (ever):	
□1 Yes	
□2 No	
Td, Tdap, DTaP, or DT (in pas	t 10 years):
□1 Yes □2 No	
Tdap (ever):	
□1 Yes	
□2 No	
Hepatitis B complete series (	ever):
□1 Yes □2 No	
□3 Immune	
Shingrix/recombinant zoster	vaccine (RZV) complete series
(ever):	, , , , ,
□1 Yes	
□2 No	ok manufa disertina Assalta manta di
	nt result during Audit period)
A1C:	
A1C Date obtained:/	
Total Cholesterol:	
HDL Cholesterol: LDL Cholesterol:	
LDL Cholesterol: Triglycerides:	
Serum Creatinine:	
	mL/min/1.73 m <sup>2</sup>
	mg/g (*Urine Albumin: Creatinine Ratio)
Local Questions [Optional]	_ mg/g ( office Albanini, eleatinine Natio)
Select one:	
□2 □6 □3 □7	 □9
Text:	